CN115501235B - 一种化合物在制备防治脱髓鞘疾病药物的应用 - Google Patents
一种化合物在制备防治脱髓鞘疾病药物的应用 Download PDFInfo
- Publication number
- CN115501235B CN115501235B CN202211174824.1A CN202211174824A CN115501235B CN 115501235 B CN115501235 B CN 115501235B CN 202211174824 A CN202211174824 A CN 202211174824A CN 115501235 B CN115501235 B CN 115501235B
- Authority
- CN
- China
- Prior art keywords
- compound
- demyelinating diseases
- formula
- medicament
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 208000016192 Demyelinating disease Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 8
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 claims abstract description 32
- 230000004069 differentiation Effects 0.000 claims abstract description 18
- 102000006386 Myelin Proteins Human genes 0.000 claims abstract description 6
- 108010083674 Myelin Proteins Proteins 0.000 claims abstract description 6
- 210000005012 myelin Anatomy 0.000 claims abstract description 6
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 6
- 230000035800 maturation Effects 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 235000015091 medicinal tea Nutrition 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004556 brain Anatomy 0.000 abstract description 7
- 210000003050 axon Anatomy 0.000 abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 210000003007 myelin sheath Anatomy 0.000 abstract description 5
- 238000009825 accumulation Methods 0.000 abstract description 4
- 230000023105 myelination Effects 0.000 abstract description 4
- 102100025535 Delta(14)-sterol reductase TM7SF2 Human genes 0.000 abstract description 3
- 101001056901 Homo sapiens Delta(14)-sterol reductase TM7SF2 Proteins 0.000 abstract description 3
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000037353 metabolic pathway Effects 0.000 abstract description 3
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 abstract description 2
- 230000008717 functional decline Effects 0.000 abstract description 2
- 230000001537 neural effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- -1 3, 5-dimethyl-1H-pyrazol-1-yl Chemical group 0.000 description 10
- 230000024245 cell differentiation Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229920001821 foam rubber Polymers 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- IZYYKGDHFNODPK-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-5-ylmethyl)-4-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-N-methylpyrrolidine-3-carboxamide Chemical compound CNC(C(CN(CC(C=C1)=CC2=C1OCC2)C1)C1C1=NC(COC)=NO1)=O IZYYKGDHFNODPK-UHFFFAOYSA-N 0.000 description 1
- BIJVTWLWOMNVAH-UHFFFAOYSA-N 2-[7-[2-(4-methoxyphenyl)ethyl]-1,3-dimethyl-2,6-dioxopurin-8-yl]sulfanylbutanoic acid Chemical compound CCC(C(O)=O)SC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCC1=CC=C(OC)C=C1 BIJVTWLWOMNVAH-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种化合物在制备防治脱髓鞘疾病药物的应用。本发明的式I~式V化合物可通过抑制TM7SF2提高胆固醇代谢途径中FF‑MAS的积累,促进少突胶质前体细胞向少突胶质细胞分化和成髓鞘;促进脱髓鞘疾病患者脑内原有少突胶质前体细胞向少突胶质细胞分化,形成髓鞘重新包裹轴突,恢复因髓鞘脱落损失引起的神经功能衰退,对脱髓鞘疾病具有治疗和/或减轻和/或预防作用。
Description
本申请为申请号202110880211.9、申请日2021年08月02日、发明名称“化合物在制备治疗和/或预防脱髓鞘疾病药物的应用”的分案申请。
技术领域
本发明属于化合物新应用技术领域,尤其涉及一种化合物在制备防治脱髓鞘疾病药物的应用。
背景技术
在脊椎动物中枢神经***中(Central nervous system,CNS),轴突髓鞘化实现神经冲动跳跃式传导,加快神经冲动传导速度。少突胶质细胞(Oligodendrocyte,OL)和施万细胞(Schwann cell)分别产生中枢神经***和外周神经***(peripheral nervoussystem,PNS)的髓鞘。其中,OL由少突胶质前体细胞(oligodendrocyte precursor cell,OPC)分化产生。多发性硬化(Multiple sclerosis,MS)、格林-巴利综合征(Guillain-Barresyndrome)、视神经脊髓炎(Neuro myelitis optica,NMO)等多种脱髓鞘疾病会引发神经轴突髓鞘损伤和脱失,进而造成神经功能缺损。正常情况下,成年个体脑内储存OPC可以被招募迁移到病灶地区并分化成OL,从而产生髓鞘包围轴突。但是在病理条件下,这一过程受到阻碍。目前以靶向免疫***的治疗方式能够减少脱髓鞘疾病中免疫介导的损伤,但是,无法促进髓鞘的再生和神经轴突的修复。
髓鞘主要成分是脂质,约占干重的70%,可保护轴突并实现神经冲动跳跃式传导,加快神经信号传导速度。成年个体脑内存有少突胶质前体细胞,但在脱髓鞘疾病病理条件下,脑内少突胶质前体细胞难以自主分化成为少突胶质细胞和产生髓鞘。因此,需要发现促进少突胶质前体细胞分化的新化合物。
发明内容
本发明旨在至少解决上述现有技术中存在的技术问题之一。为此,本发明第一个方面提出化合物或其衍生物在制备治疗和/或预防脱髓鞘疾病药物的应用,能够有效治疗和/或预防脱髓鞘疾病。
本发明的第二个方面提出了一种治疗和/或预防脱髓鞘疾病的药物组合物。
根据本发明的第一个方面,提出了下列式I~式V化合物或其衍生物在制备治疗和/或预防脱髓鞘疾病药物的应用:
其中,式I化合物的CAS号为2096197-23-6,化学名称为:3-(3,5-二甲基-1H-吡唑-1-基)-N-({1-氧代-2-[(吡啶-3-基)甲基]-1H,2H,3H,4H-吡咯[1,2-a]吡嗪-3-基}甲基)丙酰胺(3-(3,5-dimethyl-1H-pyrazol-1-yl)-N-({1-oxo-2-[(pyridin-3-yl)methyl]-1H,2H,3H,4H-pyrrolo[1,2-a]pyrazin-3-yl}methyl)propenamide);式II化合物的CAS号为1775503-94-0,化学名称为1-[(2,3-二氢-1-苯并呋喃-5-基)甲基]-4-[3-(甲氧基甲基)-1,2,4-恶二唑-5-基]-N-甲基吡咯烷-3-甲酰胺(1-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-4-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-N-methylpyrrolidine-3-carboxamide);式III化合物的CAS号为686301-37-1,化学名称为:5-(2-{6-氨基-9-[(2S,3S,4R,5S)-3,4-二羟基-5-(羟甲基)氧代兰-2-基]-9H-嘌呤-8-基}肼基-1-叶立德酮)-1,3-二嗪烷-2,4,6-三酮(5-(2-{6-amino-9-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-8-yl}hydrazin-1-ylidene)-1,3-diazinane-2,4,6-trione);式IV的CAS号为:714914-49-5,化学名称为:1,1′-(1,2-苯撑二(亚甲基))二(5-甲基嘧啶-2,4(1H,3H)-二酮)(1,1'-(1,2-phenylenebis(methylene))bis(5-methylpyrimidine-2,4(1H,3H)-dione));式V化合物的CAS号为931589-90-1,化学名称为:2-[[2,3,6,7-四氢-7-[2-(4-甲氧基苯基)乙基]-1,3-二甲基-2,6-二氧-1H-嘌呤-8-基]硫]-丁酸(2-[[2,3,6,7-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl]thio]-butanoicacid)。
本发明中,式I~式V化合物通过抑制TM7SF2提高胆固醇代谢途径中FF-MAS(Follicular Fluid Meiosis-activating Sterol,卵丘细胞分泌促减数***甾醇,CAS号为:64284-64-6)的积累,而FF-MAS的积累可以促进少突胶质前体细胞向少突胶质细胞分化和成髓鞘。
在本发明的一些实施方式中,所述衍生物包括其药学上可接受的盐、酯、水合物、溶剂化物、结晶形式、对映异构体、立体异构体、醚、代谢物和前药。
在本发明的一些优选的实施方式中,所述药学上可接受的盐包括但不仅限于无机酸盐,有机酸盐,烷基磺酸盐和芳基磺酸盐中的至少一种;优选地,所述无机酸盐包括但不仅限于盐酸盐、氢溴酸盐、硝酸盐、硫酸盐和磷酸盐中的至少一种;优选地,所述有机酸盐包括但不仅限于甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐和柠檬酸盐中的至少一种;优选地,所述烷基磺酸盐包括但不仅限于甲基磺酸盐和乙基磺酸盐中的至少一种;所述芳基磺酸盐包括但不仅限于苯磺酸盐和对甲苯磺酸盐中的至少一种。
在本发明的一些更优选的实施方式中,所述治疗和/或预防脱髓鞘疾病药物为促进髓鞘再生的药物。
在本发明的一些更优选的实施方式中,所述促进髓鞘再生的药物为促进少突胶质前体细胞分化成熟或促进髓鞘相关蛋白的表达的药物。
在本发明的一些更优选的实施方式中,所述治疗和/或预防脱髓鞘疾病药物是以所述式I~式V化合物中的任意一种作为唯一活性成分或者包含所述式I~式V化合物中的至少一种的药物组合物。
在本发明的一些更优选的实施方式中,所述治疗和/或预防脱髓鞘疾病药物中所述式I~式V化合物的任意一种的含量为0.1~99wt%;优选为1~90wt%;进一步优选为10~85wt%。
在本发明的一些更优选的实施方式中,所述治疗和/或预防脱髓鞘疾病药物为汤剂、散剂、丸剂、酒剂、锭剂、胶剂、膏药、茶剂、曲剂、糕剂、露剂、棒剂、线剂、条剂、钉剂,灸熨剂,膏剂、丹剂、微型胶囊、静脉乳剂、脂质体制剂、气雾剂、前体药制剂、注射剂、合剂、口服安瓿剂、片剂、胶囊剂、滴丸剂、乳剂、软膏剂、橡胶硬膏、膜剂、海绵剂、离子透入剂、透皮吸收剂。
根据本发明的第二个方面,提出了一种治疗和/或预防脱髓鞘疾病的药物组合物,由式I~式V化合物或其衍生物至少一种以及药学上可接受的辅料组成。
本发明的有益效果为:本发明的式I~式V化合物可通过抑制TM7SF2提高胆固醇代谢途径中FF-MAS的积累,促进少突胶质前体细胞向少突胶质细胞分化和成髓鞘;促进脱髓鞘疾病患者脑内原有少突胶质前体细胞向少突胶质细胞分化,形成髓鞘重新包裹轴突,恢复因髓鞘脱落损失引起的神经功能衰退,对脱髓鞘疾病具有治疗和/或减轻和/或预防作用。
附图说明
下面结合附图和实施例对本发明做进一步的说明,其中:
图1为本发明式I~式V化合物对少突胶质前体细胞分化促进的量效关系。
图2为本发明式I~式V化合物与DMSO阴性对照对少突胶质前体细胞分化作用的免疫荧光结果,标尺为100μm。
图3为本发明式I~式V化合物对少突胶质前体细胞分化作用的蛋白印迹结果。
具体实施方式
以下将结合实施例对本发明的构思及产生的技术效果进行清楚、完整地描述,以充分地理解本发明的目的、特征和效果。显然,所描述的实施例只是本发明的一部分实施例,而不是全部实施例,基于本发明的实施例,本领域的技术人员在不付出创造性劳动的前提下所获得的其他实施例,均属于本发明保护的范围。
实施例
式I~式V化合物对少突胶质前体细胞(OPC)分化的促进作用
实验方法:
为了研究证实式I~式V化合物对OPC分化的作用,验证式I~式V化合物可以促进OPC分化和成熟作用。
实验用细胞:原代培养的少突胶质前体细胞(OPC)。
实验用药物和抗体:
本发明药物:式I~式V化合物
阴性对照药物:DMSO
阳性对照药物:甲状腺素3(T3)
细胞培养:脱颈处死E14.5的ICR孕鼠,酒精棉球擦拭腹部后剖开,分离子宫,先后由75%酒精和PBS浸洗,转移到含有适量HBSS的60mm皿中,转至生物安全柜操作;解剖显微镜下,用镊子和手术剪从子宫中分离胎鼠。镊子撕开大脑皮肤/头骨,去掉嗅球,小脑和基底核,将剩余大脑皮层转移到含有NPC培养基的新60mm皿中。镊子剪去头,四肢,尾巴和内脏,躯干转移至另外含有冷PBS的60mm皿中,用于MEF提取;用手术剪将所有大脑皮层剪成1mm3小块,移液枪轻柔吹打,过40μm滤网,1000rpm离心5min,弃上清,加适量NPC培养基重悬,转移至100mm皿中悬浮培养(平均每皿中培养3个胎鼠提取出的细胞),计为P0代,培养2-3天或神经球直径到达100μm进行传代。
OPC分化实验:P5代神经球经Accutase酶消化成单细胞,按照4×104细胞/孔密度种到96孔板(预先多聚鸟氨酸和Laminin包被),OPC培养基培养2天将NPC诱导分化成OPC;弃掉OPC培养基,DPBS洗1次,更换为OL培养基,并分别加入0.05μM、0.1μM、1μM、20μM的式I~式V化合物,每块96孔板设阴性对照(DMSO,0.2%,v/v)和阳性对照(T3,100nM),分化3天将OPC分化成OL;将分化后的细胞用4%PFA固定,MBP(髓磷脂碱性蛋白,myelin basic protein,MBP)免疫荧光染色;染色结果用高内涵成像***Scan-R成像,以MBP+细胞百分数为指标,选取DMSO阴性对照组为标准,MBP+细胞比例高于这个标准的为可促进OPC分化。
蛋白质提取与免疫印迹分析:
P5代神经球经Accutase酶消化成单细胞,按照1.2×106细胞/孔密度种到6孔板(预先由多聚鸟氨酸和Laminin包被)。按照上述分化方法,经两天的OPC分化和三天的OL分化后提取蛋白质;弃去培养基,DPBS洗1次。加入150μL/孔RAPI裂解液,4℃静置30min;刮棒收集,14000rpm,4℃离心15min,收集上清,使用BCA试剂盒测定蛋白浓度。加入速溶型蛋白上样缓冲液(变性,还原型,5×),100℃加热10min使蛋白变性,-20℃保存或立刻使用。
配制12%分离胶,加入TEMED后摇匀。灌入玻璃板中,加入去离子水液封,室温放置30min凝固;弃去去离子水,加入浓缩胶(已加TEMED),之后***梳子,确保无气泡产生,室温放置20min凝固。冲洗胶板,放入电泳槽,加入足量电泳液,拔掉梳子,左右分别加入10μL和5μLMarker。中间加入蛋白样品。每组样品1加入15μL,同组其他样品根据BCA试剂盒测定吸光度值计算比值加入。120V恒压20min,使条带电泳至分离胶与浓缩胶分界线。之后100V电泳40min-60min至Marker充分展开。剪取合适大小的PVDF膜,浸入甲醇活化5min。加入适量转膜液至托盘,将滤纸和海绵垫浸入转膜液;撬开胶板,去除浓缩胶和周围多余分离胶。放置在滤纸上。打开转膜用夹子,按照黑面-海绵垫-滤纸-胶-PVDF膜-滤纸-海绵垫-白面放置,夹紧夹子;将夹子放入转膜槽,夹子黑面对应转膜槽黑面,白面对应转膜槽红面。倒入适量转膜液,并放两个小冰盒至转膜槽。之后置于冰中。300mA转膜1.5h。
从转膜槽中取出PVDF膜,加适量5%脱脂奶粉,室温振摇封闭2h;弃去5%脱脂奶粉,TBST洗3次,每次10min;加入适量一抗,4℃孵育过夜;吸走一抗,TBST洗3次,每次10min;加入适量二抗(2.5%脱脂奶粉稀释),室温摇晃孵育2h;吸走二抗,TBST洗3次,每次10min;发光显影成像:ECL增强化学发光液A液和B液等体积混合,均匀滴在膜上,仪器曝光成像。
结果如图1~图3所示,图1中,“**”表示为P<0.01,“***”表示为P<0.001,“****”表示为P<0.0001,当P<0.01时,与阴性对照组0.2%DMSO组比较,组间具有显著性差异。表示为可看出,式Ⅰ~式Ⅴ的MBP(少突胶质细胞成熟表达的蛋白)阳性细胞率(MBP+%)与化合物浓度之间具有相关性,其中0.05μM式Ⅰ、0.1μM式Ⅱ、0.1μM式Ⅲ、0.1μM式Ⅳ和1μM式Ⅴ与阴性对照组相比较具有最好的MBP阳性细胞率,即最好的促进少突胶质前体细胞分化活性。
图2中,蓝色表示为细胞核(由DAPI染色),红色表示为MBP,标尺为100μm,可看出,相较于阴性对照组0.2%DMSO组,式Ⅰ~式Ⅴ的MBP表达量明显升高,直接证明式Ⅰ~式Ⅴ在相应浓度下能够促进少突胶质前体细胞分化成熟。
从图3可以看出,根据MBP蛋白表达量情况,式Ⅰ~式Ⅴ的MBP表达高于阴性对照组0.2%DMSO组,即式Ⅰ~式Ⅴ促进MBP表达,表明式Ⅰ~式Ⅴ能够促进少突胶质前体细胞分化成熟。
上面对本发明实施例作了详细说明,但是本发明不限于上述实施例,在所属技术领域普通技术人员所具备的知识范围内,还可以在不脱离本发明宗旨的前提下作出各种变化。此外,在不冲突的情况下,本发明的实施例及实施例中的特征可以相互组合。
Claims (8)
1.式V化合物或其药学上可接受的盐在制备治疗和/或预防脱髓鞘疾病药物的应用:
。
2.根据权利要求1所述的应用,其特征在于:所述治疗和/或预防脱髓鞘疾病药物为促进髓鞘再生的药物。
3.根据权利要求2所述的应用,其特征在于:所述促进髓鞘再生的药物为促进少突胶质前体细胞分化成熟或促进髓鞘相关蛋白的表达的药物。
4.根据权利要求1所述的应用,其特征在于:所述治疗和/或预防脱髓鞘疾病药物是以所述式V化合物作为唯一活性成分或者包含所述式V化合物的药物组合物。
5.根据权利要求1所述的应用,其特征在于:所述治疗和/或预防脱髓鞘疾病药物中所述式V化合物的含量为0.1~99wt%。
6.根据权利要求1所述的应用,其特征在于:所述治疗和/或预防脱髓鞘疾病药物中所述式V化合物的含量为1~90 wt %。
7.根据权利要求1所述的应用,其特征在于:所述治疗和/或预防脱髓鞘疾病药物为汤剂、散剂、丸剂、酒剂、锭剂、胶剂、茶剂、曲剂、糕剂、露剂、棒剂、线剂、条剂、钉剂、灸熨剂、膏剂、丹剂、脂质体制剂、气雾剂、注射剂、合剂、片剂、胶囊剂、滴丸剂、乳剂、膜剂、海绵剂、离子透入剂、透皮吸收剂。
8.一种治疗和/或预防脱髓鞘疾病的药物组合物,其特征在于:由如权利要求1所述的式V化合物或其药学上可接受的盐至少一种以及药学上可接受的辅料组成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211174824.1A CN115501235B (zh) | 2021-08-02 | 2021-08-02 | 一种化合物在制备防治脱髓鞘疾病药物的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211174824.1A CN115501235B (zh) | 2021-08-02 | 2021-08-02 | 一种化合物在制备防治脱髓鞘疾病药物的应用 |
CN202110880211.9A CN113616657B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备治疗和/或预防脱髓鞘疾病药物的应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110880211.9A Division CN113616657B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备治疗和/或预防脱髓鞘疾病药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115501235A CN115501235A (zh) | 2022-12-23 |
CN115501235B true CN115501235B (zh) | 2023-11-07 |
Family
ID=78382175
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211173846.6A Active CN115501234B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备防治脱髓鞘疾病药物的用途 |
CN202211173609.XA Active CN115501233B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备治疗和/或预防脱髓鞘疾病药物的用途 |
CN202211174824.1A Active CN115501235B (zh) | 2021-08-02 | 2021-08-02 | 一种化合物在制备防治脱髓鞘疾病药物的应用 |
CN202211173737.4A Active CN115501227B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备防治脱髓鞘疾病药物的应用 |
CN202110880211.9A Active CN113616657B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备治疗和/或预防脱髓鞘疾病药物的应用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211173846.6A Active CN115501234B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备防治脱髓鞘疾病药物的用途 |
CN202211173609.XA Active CN115501233B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备治疗和/或预防脱髓鞘疾病药物的用途 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211173737.4A Active CN115501227B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备防治脱髓鞘疾病药物的应用 |
CN202110880211.9A Active CN113616657B (zh) | 2021-08-02 | 2021-08-02 | 化合物在制备治疗和/或预防脱髓鞘疾病药物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (5) | CN115501234B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108379246A (zh) * | 2018-05-16 | 2018-08-10 | 中国人民解放军第二军医大学 | 莽草酸在制备预防或治疗脱髓鞘疾病药物中的应用 |
WO2019172969A1 (en) * | 2018-03-08 | 2019-09-12 | The Scripps Research Institute | Methods for promoting myelination and for treating demyelinating diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001267882A1 (en) * | 2000-06-30 | 2002-01-14 | Chugai Seiyaku Kabushiki Kaisha | Preventives and remedies for diseases in association with demyelination |
WO2004037159A2 (en) * | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
US9551036B2 (en) * | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
WO2016039339A1 (ja) * | 2014-09-08 | 2016-03-17 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
MA45793A (fr) * | 2016-07-27 | 2021-03-24 | Univ Case Western Reserve | Composés et procédés de stimulation de la myélinisation |
AU2017308131A1 (en) * | 2016-08-12 | 2019-03-07 | The Regents Of The University Of California | Remyelination therapies |
WO2019126759A1 (en) * | 2017-12-22 | 2019-06-27 | Convelo Therapeutics, Inc. | Compounds and methods of promoting myelination |
WO2020072456A1 (en) * | 2018-10-02 | 2020-04-09 | Case Western Reserve University | Compounds for treating myelin related disorders |
-
2021
- 2021-08-02 CN CN202211173846.6A patent/CN115501234B/zh active Active
- 2021-08-02 CN CN202211173609.XA patent/CN115501233B/zh active Active
- 2021-08-02 CN CN202211174824.1A patent/CN115501235B/zh active Active
- 2021-08-02 CN CN202211173737.4A patent/CN115501227B/zh active Active
- 2021-08-02 CN CN202110880211.9A patent/CN113616657B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019172969A1 (en) * | 2018-03-08 | 2019-09-12 | The Scripps Research Institute | Methods for promoting myelination and for treating demyelinating diseases |
CN108379246A (zh) * | 2018-05-16 | 2018-08-10 | 中国人民解放军第二军医大学 | 莽草酸在制备预防或治疗脱髓鞘疾病药物中的应用 |
Non-Patent Citations (2)
Title |
---|
Diverse Chemical Scaffolds Enhance Oligodendrocyte Formation by Inhibiting CYP51, TM7SF2, or EBP;Dharmaraja Allimuthu等;Cell Chemical Biology;第26卷;593-599 * |
复髓鞘机制及其在多发性硬化症脱髓鞘模型中的研究进展;郑双双等;浙江大学学报(医学版);第49卷(第4期);524-530 * |
Also Published As
Publication number | Publication date |
---|---|
CN115501234A (zh) | 2022-12-23 |
CN113616657A (zh) | 2021-11-09 |
CN113616657B (zh) | 2022-12-20 |
CN115501227A (zh) | 2022-12-23 |
CN115501233A (zh) | 2022-12-23 |
CN115501234B (zh) | 2023-08-08 |
CN115501235A (zh) | 2022-12-23 |
CN115501233B (zh) | 2023-11-07 |
CN115501227B (zh) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022084697A (ja) | 神経変性を治療するための方法及び組成物 | |
JP2021138656A (ja) | 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質 | |
CN118147051A (zh) | 用于促进干细胞来源外泌体产生和增加干性的包含白藜芦醇的组合物 | |
JP2021522822A (ja) | 幹細胞由来の細胞培養物、幹細胞由来の三次元組織製品、及びそれらの製造及び使用方法 | |
CN115501235B (zh) | 一种化合物在制备防治脱髓鞘疾病药物的应用 | |
JP2006518732A (ja) | PTEN阻害剤またはMaxi−Kチャンネルオープナー | |
CN102625707A (zh) | Hip/pap或其衍生物的新应用 | |
Ren et al. | Intracerebral neural stem cell transplantation improved the auditory of mice with presbycusis | |
JP6994613B2 (ja) | 神経発生性疾患および障害を処置する方法 | |
CN108159045B (zh) | 红波罗花碱a及其衍生物在制备预防或治疗中枢神经***疾病药物中的应用 | |
US20060269568A1 (en) | Reduction of embryonic neural tube defects by pre-or early-administration of germination-activated sporoderm-broken ganoderma lucidum spores to pregnant female | |
CN101489543A (zh) | 提高受试者的学习和/或记忆能力的3-羟基脂肪酸及其衍生物 | |
US20160228470A1 (en) | Composition comprising neural cell and elastin-like polypeptide for treating parkinson's disease | |
JP4232866B2 (ja) | 細胞障害抑制剤 | |
CN108685906A (zh) | 小分子化合物p7c3的新应用 | |
CN116747230A (zh) | 促进髓鞘再生的化合物及其在治疗阿尔茨海默病中应用 | |
CN108938631B (zh) | Sag在制备治疗发育期缺氧缺血脑损伤疾病的药物中的应用 | |
WO2011140682A1 (zh) | (2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途 | |
JP2007269650A (ja) | 神経細胞生長発育及び神経幹細胞生成促進化合物 | |
CN111973606B (zh) | 一种化合物治疗血管增生以及糖尿病视网膜病变的新用途 | |
CN116036239B (zh) | Nep1-40在制备特异性抑制幻觉作用的药物中的应用 | |
CN111514145B (zh) | 一种hipk2基因表达的抑制剂、试剂盒及其应用 | |
CN106631871A (zh) | 一种神经酰胺类化合物和应用 | |
CN109689048A (zh) | 促进胚胎植入和预防流产的催产素拮抗剂给药方案 | |
CN116459261A (zh) | Lit-001在治疗焦虑疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |